안과용 약물전달 시스템 시장 규모, 점유율, 동향 분석 보고서 : 기술별, 전달 경로별, 생산 기술별, 재료별, 지역별, 부문별 예측(2025-2030년)

Ophthalmic Drug Delivery Systems Market Growth & Trends:

The global ophthalmic drug delivery systems market size is projected to reach USD 23.36 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.6% from 2025 to 2030. Factors such as growing prevalence of ophthalmic diseases, rise in number of ophthalmic procedures that require attentive post procedural care and increase in need to deliver controlled dosage forms for pediatric and geriatric population are anticipated to propel the growth of the market. In addition, immense focus on technological advancements is further helping the market to grow at a significant rate. For instance, manufacturers' instant focus on nanotechnology has helped to deliver error-free drug delivery and increase the penetration level of the drug at the target site.

The market observed a sudden fall in sales of ophthalmic drug delivery systems during the first half of the COVID-19 pandemic. The lockdowns across different countries and various restrictions led down by the government led to fall in number of patient's visits to the hospitals and clinics. Moreover, the disruption in supply chains also led to a shortage of these products which indicates an overall negative impact on the market. However, with the government's initiatives to curb the spread of the virus and limit the negative consequences it possesses via mass vaccination programs and heavy investment in R&D activities, the market is expected to recover over the forecast period.

Ophthalmic Drug Delivery Systems Market Report Highlights:

• The eye drops segment dominated the market with highest revenue share in 2024 as eye drops are often recommended as the first line of treatment in most of the ophthalmic procedures to control the effect of the disease as it is the most convenient and patient compliant technology.
• The intraocular segment held the highest revenue share in 2024 owing to the advantages it offers such as sterilization, less irritation, ease of eye drops formulation and enhancement in ocular bioavailability of drugs that are insoluble in tear fluid.
• On the basis of production technology, the formulation segment accounted for highest market share in 2024 owing to increase in adoption of topical eye drops which is produced through the formulation technology.
• Based on material, the hydrogels segment held the highest market share in 2024 owing to the advantages it offers over other materials.
• North America accounted for highest market share in 2024 due to increasing incidence of ophthalmic disorders, presence of skilled professionals and various initiatives undertaken by the government agencies to prevent blindness in the region.
• The COVID-19 pandemic has a negative impact on the market. Due to change in healthcare priorities, social distancing, worldwide lockdowns led to reduced patient visits to the hospitals and clinics.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Technology Segment
  • 1.2.2. Delivery Route Segment
  • 1.2.3. Production Technology Segment
  • 1.2.4. Material Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Segment Snapshot
• 2.4. Competitive Insights Landscape

Chapter 3. Ophthalmic Drug Delivery Systems Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Ophthalmic Drug Delivery Systems Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Ophthalmic Drug Delivery Systems Market: Technology Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Ophthalmic Drug Delivery Systems Market Technology Movement Analysis
• 4.3. Global Ophthalmic Drug Delivery Systems Market Size & Trend Analysis, by Technology, 2018 - 2030 (USD Billion)
• 4.4. Eye Drops
  • 4.4.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.5. Contact Lenses
  • 4.5.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.6. Punctal Plugs
  • 4.6.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.7. Episcleral Implants
  • 4.7.1.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.8. Intraviteal Implants
  • 4.8.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.9. Injectable Particulate Systems
  • 4.9.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.10. Iontophoresis
  • 4.10.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.11. Micro-Electromechanical
  • 4.11.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.12. Nano careers
  • 4.12.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.13. Nano microparticles
  • 4.13.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.14. Microneedles
  • 4.14.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.15. Hydrogels
  • 4.15.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.16. Others
  • 4.16.1. Market estimates and forecast 2018 - 2030 (USD Million)

Chapter 5. Ophthalmic Drug Delivery Systems Market: Delivery Route Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Ophthalmic Drug Delivery Systems Market Delivery Route Movement Analysis
• 5.3. Global Ophthalmic Drug Delivery Systems Market Size & Trend Analysis, by Delivery Route, 2018 - 2030 (USD Billion)
• 5.4. Electrospinning
  • 5.4.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 5.5. 3D Printing
  • 5.5.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 5.6. Extrusion
  • 5.6.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 5.7. Formulation
  • 5.7.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 5.8. Micropatterning
  • 5.8.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 5.9. Compression molding
  • 5.9.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 5.10. Others
  • 5.10.1. Market estimates and forecast 2018 - 2030 (USD Million)

Chapter 6. Ophthalmic Drug Delivery Systems Market: Production Technology Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Ophthalmic Drug Delivery Systems Market Production Technology Movement Analysis
• 6.3. Global Ophthalmic Drug Delivery Systems Market Size & Trend Analysis, by Production Technology, 2018 - 2030 (USD Billion)
• 6.4. Liposomes
  • 6.4.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 6.5. Collagen
  • 6.5.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 6.6. PLA-PEG
  • 6.6.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 6.7. PDO/PVA
  • 6.7.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 6.8. Hydrogels
  • 6.8.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 6.9. TMC
  • 6.9.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 6.10. Polyorthoesters
  • 6.10.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 6.11. PLGA
  • 6.11.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 6.12. Fatty acids
  • 6.12.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 6.13. Others
  • 6.13.1. Market estimates and forecast 2018 - 2030 (USD Million)

Chapter 7. Ophthalmic Drug Delivery Systems Market: Material Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Ophthalmic Drug Delivery Systems Market Material Movement Analysis
• 7.3. Global Ophthalmic Drug Delivery Systems Market Size & Trend Analysis, by Material, 2018 - 2030 (USD Billion)
• 7.4. Liposomes
  • 7.4.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 7.5. Collagen
  • 7.5.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 7.6. PLA-PEG
  • 7.6.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 7.7. PDO/PVA
  • 7.7.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 7.8. Hydrogels
  • 7.8.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 7.9. TMC
  • 7.9.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 7.10. Polyorthoesters
  • 7.10.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 7.11. PLGA
  • 7.11.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 7.12. Fatty acids
  • 7.12.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 7.13. Others
  • 7.13.1. Market estimates and forecast 2018 - 2030 (USD Million)

Chapter 8. Ophthalmic Drug Delivery Systems Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2023 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Market Size, & Forecasts Trend Analysis, 2018 - 2030:
• 8.4. North America
  • 8.4.1. U.S.
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Competitive scenario
    • 8.4.1.3. Regulatory framework
    • 8.4.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Billion)
  • 8.4.2. Canada
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Competitive scenario
    • 8.4.2.3. Regulatory framework
    • 8.4.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Billion)
  • 8.4.3. Mexico
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Competitive scenario
    • 8.4.3.3. Regulatory framework
    • 8.4.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Billion)
• 8.5. Europe
  • 8.5.1. UK
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Competitive scenario
    • 8.5.1.3. Regulatory framework
    • 8.5.1.4. UK market estimates and forecasts 2018 - 2030 (USD Billion)
  • 8.5.2. Germany
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Competitive scenario
    • 8.5.2.3. Regulatory framework
    • 8.5.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Billion)
  • 8.5.3. France
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Competitive scenario
    • 8.5.3.3. Regulatory framework
    • 8.5.3.4. France market estimates and forecasts 2018 - 2030 (USD Billion)
  • 8.5.4. Italy
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Competitive scenario
    • 8.5.4.3. Regulatory framework
    • 8.5.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Billion)
  • 8.5.5. Spain
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Competitive scenario
    • 8.5.5.3. Regulatory framework
    • 8.5.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Billion)
  • 8.5.6. Denmark
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Competitive scenario
    • 8.5.6.3. Denmark market estimates and forecasts 2018 - 2030 (USD Billion)
  • 8.5.7. Sweden
    • 8.5.7.1. Key country dynamics
    • 8.5.7.2. Competitive scenario
    • 8.5.7.3. Regulatory framework
    • 8.5.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Billion)
  • 8.5.8. Norway
    • 8.5.8.1. Key country dynamics
    • 8.5.8.2. Competitive scenario
    • 8.5.8.3. Regulatory framework
    • 8.5.8.4. Norway market estimates and forecasts 2018 - 2030 (USD Billion)
• 8.6. Asia Pacific
  • 8.6.1. Japan
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Competitive scenario
    • 8.6.1.3. Regulatory framework
    • 8.6.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Billion)
  • 8.6.2. China
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Competitive scenario
    • 8.6.2.3. Regulatory framework
    • 8.6.2.4. China market estimates and forecasts 2018 - 2030 (USD Billion)
  • 8.6.3. India
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Competitive scenario
    • 8.6.3.3. Regulatory framework
    • 8.6.3.4. India market estimates and forecasts 2018 - 2030 (USD Billion)
  • 8.6.4. Australia
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Competitive scenario
    • 8.6.4.3. Regulatory framework
    • 8.6.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Billion)
  • 8.6.5. South Korea
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Competitive scenario
    • 8.6.5.3. Regulatory framework
    • 8.6.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Billion)
  • 8.6.6. Thailand
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Competitive scenario
    • 8.6.6.3. Regulatory framework
    • 8.6.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Billion)
• 8.7. Latin America
  • 8.7.1. Brazil
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Competitive scenario
    • 8.7.1.3. Regulatory framework
    • 8.7.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Billion)
  • 8.7.2. Argentina
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Competitive scenario
    • 8.7.2.3. Regulatory framework
    • 8.7.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Billion)
• 8.8. MEA
  • 8.8.1. South Africa
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Competitive scenario
    • 8.8.1.3. Regulatory framework
    • 8.8.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Billion)
  • 8.8.2. Saudi Arabia
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Competitive scenario
    • 8.8.2.3. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Billion)
  • 8.8.3. UAE
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Competitive scenario
    • 8.8.3.3. Regulatory framework
    • 8.8.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Billion)
  • 8.8.4. Kuwait
    • 8.8.4.1. Key country dynamics
    • 8.8.4.2. Competitive scenario
    • 8.8.4.3. Regulatory framework
    • 8.8.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Billion)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2023
• 9.4. List of Key Certification Providers/Scheme Owners
• 9.5. Company Profiles/Listing
  • 9.5.1. Ocular Therapeutix Inc.
    • 9.5.1.1. Company overview
    • 9.5.1.2. Financial performance
    • 9.5.1.3. Technology benchmarking
    • 9.5.1.4. Strategic initiatives
  • 9.5.2. Allergan plc.
    • 9.5.2.1. Company overview
    • 9.5.2.2. Financial performance
    • 9.5.2.3. Technology benchmarking
    • 9.5.2.4. Strategic initiatives
  • 9.5.3. Santen Pharmaceutical Co. Ltd.
    • 9.5.3.1. Company overview
    • 9.5.3.2. Financial performance
    • 9.5.3.3. Technology benchmarking
    • 9.5.3.4. Strategic initiatives
  • 9.5.4. Envisia Therapeutics
    • 9.5.4.1. Company overview
    • 9.5.4.2. Financial performance
    • 9.5.4.3. Technology benchmarking
    • 9.5.4.4. Strategic initiatives
  • 9.5.5. pSivida
    • 9.5.5.1. Company overview
    • 9.5.5.2. Financial performance
    • 9.5.5.3. Technology benchmarking
    • 9.5.5.4. Strategic initiatives
  • 9.5.6. Clearside Biomedical
    • 9.5.6.1. Company overview
    • 9.5.6.2. Financial performance
    • 9.5.6.3. Technology benchmarking
    • 9.5.6.4. Strategic initiatives
  • 9.5.7. Oculis Pharma
    • 9.5.7.1. Company overview
    • 9.5.7.2. Financial performance
    • 9.5.7.3. Technology benchmarking
    • 9.5.7.4. Strategic initiatives
  • 9.5.8. Valeant Pharmaceuticals
    • 9.5.8.1. Company overview
    • 9.5.8.2. Financial performance
    • 9.5.8.3. Technology benchmarking
    • 9.5.8.4. Strategic initiatives
  • 9.5.9. AptarGroup, Inc.
  • 9.5.9. Company overview
    • 9.5.9.1. Financial performance
    • 9.5.9.2. Technology benchmarking
    • 9.5.9.3. Strategic initiatives